pfs25-imx313
Vaccineexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2015 (NCT02532049)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Plasmodium falciparumImmunity, active
Plasmodium falciparum immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mva pfs25-imx313
- pfs25-imx313
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06549257 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2024 | European and Developing Countries Clinical Trials Partnership (EDCTP), University of Oxford |
| NCT05270265 | Early Phase 1 (Phase 1) | Feb 9, 2022 | Churchill Hospital, Oxford, University of Oxford |
| NCT04271306 | Phase 1 | Apr 30, 2020 | Ifakara Health Institute, University of Oxford |
| NCT04130282 | Phase 1 | Sep 27, 2019 | University of Oxford |
| NCT02532049 | Phase 1 | Oct 1, 2015 | University of Oxford |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Oxford | Academic/Hospital | 5 | 5 | 2 | 2015 |
| Churchill Hospital, Oxford | Academic/Hospital | 1 | 0 | 1 | 2022 |
| European and Developing Countries Clinical Trials Partnership (EDCTP) | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Ifakara Health Institute | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1